## Clinical Context This patient has acute decompensated heart failure with cardiogenic shock (hypotension, pulmonary edema, low ejection fraction) in the immediate post-MI period with symptomatic bradycardia and hypotension. ## Key Point: **Beta-blockers are contraindicated in acute decompensated heart failure with hemodynamic instability.** Initiating or escalating beta-blockers in this setting will worsen cardiac output and worsen shock. ## Immediate Management Priority 1. Stabilize hemodynamics first (inotropic support, diuretics, afterload reduction) 2. Correct bradycardia and hypotension 3. Once hemodynamically stable (BP > 90 mmHg systolic, HR > 55 bpm, no pulmonary edema), introduce beta-blockers cautiously at low dose ## High-Yield: **Timing of beta-blocker initiation in post-MI heart failure:** - Acute phase with cardiogenic shock → **WITHHOLD** - Stable phase (after 24–48 hours, hemodynamically compensated) → **Start low-dose, uptitrate slowly** - Chronic heart failure with reduced EF → **Essential therapy** (carvedilol, bisoprolol, metoprolol succinate) ## Clinical Pearl: Dobutamine (β~1~-agonist) increases contractility and heart rate, counteracting the negative inotropic effect of beta-blockers. It is the agent of choice for cardiogenic shock pending stabilization. ## Why Not the Other Options? - **Option 0 (metoprolol 25 mg daily):** Initiating beta-blocker in acute shock will worsen hypotension and reduce cardiac output further. - **Option 2 (carvedilol 3.125 mg):** Although carvedilol is ideal for chronic heart failure, this patient is acutely unstable and requires inotropic support first. - **Option 3 (atropine then beta-blocker):** Atropine is not indicated; bradycardia is a sign of cardiogenic shock, not a primary conduction problem. Treating the underlying shock is the priority.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.